# Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

> **NCT05962398** · — · ENROLLING_BY_INVITATION · sponsor: **CSL Behring** · enrollment: 56 (estimated)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** AAV5-hFIXco-Padua

## Key facts

- **NCT ID:** NCT05962398
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-08-30
- **Primary completion:** 2035-03-23
- **Final completion:** 2035-03-23
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962398, "Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05962398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*